FDA Approves Teclistamab for Relapsed or Refractory Multiple Myeloma

$FDA Approves Teclistamab for Relapsed or Refractory Multiple Myeloma$

On October 25, 2022, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to teclistamab-cqyv for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior treatments.

For more information, read the FDA announcement.

Posted 10/27/2022